Document And Entity Information	6 Months Ended
Document And Entity Information	Jun. 30, 2011	Jul. 25, 2011
Document and Entity Information
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2011
Document Fiscal Year Focus	2011
Document Fiscal Period Focus	Q2
Entity Filer Category	Large Accelerated Filer
Entity Registrant Name	INTEGRA LIFESCIENCES HOLDINGS CORP
Entity Central Index Key	0000917520
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		27,517,563

Condensed Consolidated Statements Of Operations (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2011	Jun. 30, 2010	Jun. 30, 2011	Jun. 30, 2010
Condensed Consolidated Statements Of Operations
Total revenues	$ 193,329	$ 178,595	$ 374,370	$ 351,293
Costs And Expenses:
Cost of product revenues	72,838	64,464	137,759	127,688
Research and development	12,709	11,761	24,862	23,062
Selling, general and administrative	95,732	74,216	175,816	146,727
Intangible asset amortization	4,050	3,575	7,061	6,594
Total costs and expenses	185,329	154,016	345,498	304,071
Operating income	8,000	24,579	28,872	47,222
Interest income	127	52	200	113
Interest expense	(6,722)	(4,300)	(12,191)	(8,841)
Other income (expense), net	593	763	(50)	1,909
Income before income taxes	1,998	21,094	16,831	40,403
Income tax expense	1,299	5,937	4,645	10,024
Net income	$ 699	$ 15,157	$ 12,186	$ 30,379
Basic net income per common share	$ 0.02	$ 0.51	$ 0.41	$ 1.02
Diluted net income per common share	$ 0.02	$ 0.50	$ 0.40	$ 1.00
Weighted Average Common Shares Outstanding (See Note 11):
Basic	29,556	29,855	29,559	29,672
Diluted	30,178	30,399	30,154	30,282

Condensed Consolidated Balance Sheets (USD $) In Thousands, unless otherwise specified	6 Months Ended	12 Months Ended
	Jun. 30, 2011	Dec. 31, 2010
Current Assets:
Cash and cash equivalents	$ 137,279	$ 128,763
Trade accounts receivable, net of allowances of $6,825 and $7,322	116,179	106,005
Inventories, net	174,460	146,928
Deferred tax assets	35,072	35,284
Prepaid expenses and other current assets	32,794	27,869
Total current assets	495,784	444,849
Property, plant and equipment, net	115,667	99,456
Intangible assets, net	230,935	194,904
Goodwill	285,376	261,928
Deferred tax assets	12,464	7,894
Other assets	13,630	10,102
Total assets	1,153,856	1,019,133
Current Liabilities:
Borrowings under senior credit facility		108,438
Accounts payable, trade	47,894	27,783
Deferred revenue	3,367	4,444
Accrued compensation	25,063	27,562
Accrued expenses and other current liabilities	41,684	33,630
Total current liabilities	118,008	201,857
Long-term borrowings under senior credit facility	144,375	139,688
Long-term convertible securities	345,687	155,154
Deferred tax liabilities	10,317	10,645
Other liabilities	16,652	11,826
Total liabilities	635,039	519,170
Commitments and contingencies
Stockholders' Equity:
Preferred Stock; no par value; 15,000 authorized shares; none outstanding
Common stock; $0.01 par value; 60,000 authorized shares; 35,860 and 35,745 issued at June 30, 2011 and December 31, 2010, respectively	360	359
Additional paid-in capital	598,249	552,227
Treasury stock, at cost; 8,425 shares and 7,212 shares at June 30, 2011 and December 31, 2010, respectively	(340,667)	(283,658)
Accumulated Other Comprehensive (Loss) Income:
Foreign currency translation adjustment	17,530	(870)
Pension liability adjustment, net of tax	(586)	(771)
Unrealized loss on derivatives, net of tax	(1,087)	(154)
Retained earnings	245,018	232,830
Total stockholders' equity	518,817	499,963
Total liabilities and stockholders' equity	$ 1,153,856	$ 1,019,133

Condensed Consolidated Balance Sheets (Parenthetical) (USD $) In Thousands, except Per Share data, unless otherwise specified	Jun. 30, 2011	Dec. 31, 2010
Condensed Consolidated Balance Sheets
Trade accounts receivable, allowances	$ 6,825	$ 7,322
Preferred Stock, par value	$ 0.00	$ 0.00
Preferred Stock, authorized shares	15,000	15,000
Preferred Stock, outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	60,000	60,000
Common stock, shares issued	35,860	35,745
Treasury stock, shares	8,425	7,212

Condensed Consolidated Statements Of Cash Flows (USD $) In Thousands, unless otherwise specified	6 Months Ended
	Jun. 30, 2011	Jun. 30, 2010
OPERATING ACTIVITIES:
Net Income	$ 12,186	$ 30,379
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	24,451	18,954
Deferred income tax benefit	(5,209)	(375)
Amortization of debt issuance costs	1,838	674
Non-cash interest expense	3,632	3,941
Payment of accreted interest		(6,599)
Loss on disposal of property and equipment		447
Share-based compensation	15,863	7,520
Excess tax benefits from stock-based compensation arrangements	(778)	(3,474)
Changes in assets and liabilities, net of business acquisitions:
Accounts receivable	(701)	2,687
Inventories	(9,550)	(7,754)
Prepaid expenses and other current assets	1,192	(3,877)
Other non-current assets	(125)	202
Accounts payable, accrued expenses and other current liabilities	4,424	6,041
Deferred revenue	(1,108)	(715)
Other non-current liabilities	(277)	(556)
Net cash provided by operating activities	45,838	47,495
INVESTING ACTIVITIES:
Cash used in business acquisition, net of cash acquired	(80,799)	(2,421)
Purchases of property and equipment	(13,138)	(11,691)
Net cash used in investing activities	(93,937)	(14,112)
FINANCING ACTIVITIES:
Borrowings under senior credit facility	85,000	75,000
Repayments under senior credit facility	(188,750)	(15,000)
Proceeds from liability component of convertible notes issuance	186,830
Proceeds from equity component of convertible notes issuance	43,170
Repurchase of liability component of convertible notes		(71,351)
Proceeds from sale of stock purchase warrants	28,451
Purchase of option hedge on convertible notes	(42,895)
Debt issuance costs	(8,005)
Purchases of treasury stock	(57,009)
Proceeds from exercised stock options	3,297	4,633
Excess tax benefits from stock-based compensation arrangements	778	3,474
Net cash provided by (used in) financing activities	50,867	(3,244)
Effect of exchange rate changes on cash and cash equivalents	5,748	(8,412)
Net change in cash and cash equivalents	8,516	21,727
Cash and cash equivalents at beginning of period	128,763	71,891
Cash and cash equivalents at end of period	$ 137,279	$ 93,618

Basis Of Presentation	6 Months Ended
Basis Of Presentation	Jun. 30, 2011
Basis Of Presentation
Basis Of Presentation	1. BASIS OF PRESENTATION General The terms "we," "our," "us," "Company" and "Integra" refer to Integra LifeSciences Holdings Corporation, a Delaware corporation, and its subsidiaries unless the context suggests otherwise. In the opinion of management, the June 30, 2011 unaudited condensed consolidated financial statements contain all adjustments (consisting only of normal recurring adjustments) necessary for a fair statement of the financial position, results of operations and cash flows of the Company. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. These unaudited condensed consolidated financial statements should be read in conjunction with the Company's consolidated financial statements for the year ended December 31, 2010 included in the Company's Annual Report on Form 10-K. The December 31, 2010 condensed consolidated balance sheet was derived from audited financial statements but does not include all disclosures required by accounting principles generally accepted in the United States. Operating results for the three- and six-month periods ended June 30, 2011 are not necessarily indicative of the results to be expected for the entire year. The preparation of consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amount of assets and liabilities, the disclosure of contingent liabilities, and the reported amounts of revenues and expenses. Significant estimates affecting amounts reported or disclosed in the consolidated financial statements include allowances for doubtful accounts receivable and sales returns and allowances, net realizable value of inventories, valuation of intangible assets including in-process research and development, amortization periods for acquired intangible assets, discount rates and estimated projected cash flows used to value and test impairments of long-lived assets and goodwill, estimates of projected cash flows and depreciation and amortization periods for long-lived assets, computation of taxes, valuation allowances recorded against deferred tax assets, the valuation of stock-based compensation, valuation of pension assets and liabilities, valuation of derivative instruments, valuation of the equity component of convertible debt instruments, and loss contingencies. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the current circumstances. Actual results could differ from these estimates. Certain amounts from the prior year's financial statements have been reclassified in order to conform to the current year's presentation. Recently Issued Accounting Standards On June 16, 2011 the Financial Accounting Standards Board issued Accounting Standards Update No. 2011-05, Presentation of Comprehensive Income; this standard eliminates the option to report other comprehensive income and its components in the statement of changes in equity. The Company can elect to present items of net income and other comprehensive income in one continuous statement, or in two consecutive statements. Each component of net income and each component of other comprehensive income, together with totals for comprehensive income and its two parts – net income and other comprehensive income – would need to be displayed under either alternative, and the statements would need to be presented with equal prominence as the other primary financial statements. This standard does not change: 1) the items that constitute net income and other comprehensive income, 2) when an item of other comprehensive income must be reclassified to net income, or 3) the computation for earnings-per-share - which will continue to be based on net income. This standard is effective for fiscal years beginning after December 15, 2011, and the Company has not yet determined which method it will elect upon adoption. On May 12, 2011 the Financial Accounting Standards Board issued Accounting Standards Update No. 2011-04 - Fair Value Measurement (Topic 820): Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRS. This standard merges many aspects of fair value measurement guidance by amending U.S. GAAP and creating a new standard under International Financial Reporting Standards. The primary changes to U.S. GAAP include: 1) clarifying the valuation premise of highest and best use, 2) clarifying how portfolios of financial instruments are measured, 3) clarifying the use of blockage factors and other premiums and discounts, and 4) increasing the disclosure requirements in a number of circumstances. This standard is effective for fiscal years beginning after December 15, 2011, and the Company believes the standard will not have a material impact on the Company's results. Supplemental Cash Flow Information During the six months ended June 30, 2010, 282,086 stock options were exercised, whereby in lieu of a cash payment for the exercise price, an option holder tendered 73,546 shares of Company stock that had a fair market value of approximately $3.1 million. These tendered shares were then immediately retired.

- Definition

Description containing the entire organization, consolidation and basis of presentation of financial statements disclosure. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.

+ References+ Details

Business And Asset Acquisitions

6 Months Ended

Jun. 30, 2011

Business And Asset Acquisitions

Business And Asset Acquisitions

2. BUSINESS ACQUISITIONS

SeaSpine, Inc.

On May 23, 2011, the Company acquired all of the outstanding common stock of SeaSpine, Inc. ("SeaSpine") for $89.0 million, subject to certain working capital adjustments and indemnification holdbacks totaling $8.0 million which have been accrued at June 30, 2011. SeaSpine is based in Vista, California and designs, develops and manufactures spinal fixation products and synthetic bone substitute products.

The following summarizes the allocation of the purchase price based on fair value of the assets acquired and liabilities assumed (in thousands):


Cash	$	201
Inventory		14,900
Accounts receivable		7,608
Other current assets		623
Property, plant and equipment		9,177
Deferred tax asset—long term		302
Intangible assets:			Wtd. Avg. Life:
Technology		3,000	8 years
Customer relationships		41,200	13 years
Non-compete agreements		1,900	4 years
Brand name		300	1 year
Goodwill		14,897

Total assets acquired		94,108
Accounts payable and other liabilities		5,108

Net assets acquired	$	89,000

Management determined the fair value of assets acquired during the second quarter of 2011. The goodwill recorded in connection with this acquisition is based on the benefits the Company expects to generate from SeaSpine's future cash flows. For tax purposes, the Company is treating the acquisition as an asset acquisition; therefore, the goodwill will be deductible for tax purposes. The impact of the SeaSpine acquisition is not material to the consolidated operating results of the Company; therefore, the pro-forma impact of the acquisition has not been presented.

Integra Neurosciences Pty Ltd.

In October 2008 the Company acquired Integra Neurosciences Pty Ltd. in Australia and Integra Neurosciences Pty Ltd. in New Zealand for $4.0 million (6.0 million Australian dollars) in cash at closing, $0.3 million in acquisition expenses and working capital adjustments, and up to $2.1 million based on the exchange rates in effect at the time of the acquisition (3.1 million Australian dollars) in future payments based on the performance of business in the three years after closing. The Company paid approximately $0.9 million (1.0 million Australian dollars) of this potential revenue performance obligation in November 2009 for the first revenue performance year, and another $1.0 million (1.0 million Australian dollars) in December 2010 for the second revenue performance year. The Company accrued $1.1 million (1.0 million Australian dollars) at June 30, 2011 for the third revenue performance year.

Theken

In August 2008 the Company acquired Theken Spine, LLC, Theken Disc, LLC and Therics, LLC (collectively, "Integra Spine") for $75.0 million in cash, subject to certain adjustments, acquisition expenses of $2.4 million, working capital adjustments of $3.9 million, and up to $125.0 million in future payments based on the revenue performance of the business in each of the two years after closing. The Company paid approximately $52.0 million for the first year revenue performance obligation in November 2009. From November 2009 through June 30, 2011 the Company has accrued a total of $4.6 million to settle a dispute related to a disagreement in the calculation of "trade sales" used in determining the revenue performance payment for the first year revenue performance obligation (see Note 14, "Commitments and Contingencies"). There are no amounts due for the second performance year.

Inventories

6 Months Ended

Jun. 30, 2011

Inventories

Inventories

3. INVENTORIES

Inventories, net consisted of the following:


	June 30,		December 31,
	2011		2010
	(In thousands)
Finished goods	$	109,065	$	87,508
Work-in process		35,444		31,536
Raw materials		29,951		27,884

	$	174,460	$	146,928

Goodwill And Other Intangible Assets

6 Months Ended

Jun. 30, 2011

Goodwill And Other Intangible Assets

Goodwill And Other Intangible Assets

4. GOODWILL AND OTHER INTANGIBLE ASSETS

Changes in the carrying amount of goodwill for the six months ended June 30, 2011 were as follows (in thousands):


Goodwill	$	261,928
Accumulated impairment losses		—


Goodwill at December 31, 2010		261,928

SeaSpine acquisition		14,897
Integra Spine earnout		1,200
Integra Neurosciences Pty Ltd. earnout		1,059
Foreign currency translation		6,292


Goodwill at June 30, 2011	$	285,376

The Company performs its assessment of the recoverability of goodwill annually during the second quarter and it is based upon a comparison of the carrying value of goodwill with its estimated fair value. The Company performed its most recent assessment during the second quarter of 2011 which resulted in no impairment.

The Company performs its assessment of the recoverability of indefinite-live intangible assets annually during the second quarter and it is based upon a comparison of the carrying value of such assets to their estimated fair values. The Company performed its most recent assessment during the second quarter of 2011 which resulted in an impairment of $0.9 million related to one brand name asset that will no longer be used as part of our re-branding strategy. This charge has been recorded as a component of amortization expense.

During the six months ended June 30, 2011, the Company recorded impairment charges to definite lived intangible assets of $1.6 million related to technology assets whose related products are being discontinued and $0.2 million related to a brand name that will no longer be used because of our re-branding strategy. The Company has recorded the charges as a component of cost of product revenues and amortization expense, respectively.

The components of the Company's identifiable intangible assets were as follows (dollars in thousands):


	Weighted Average Life	June 30, 2011							December 31, 2010
	Weighted Average Life	Cost		Accumulated Amortization			Net		Cost		Accumulated Amortization			Net
Completed technology	12 years	$	72,133	$	(32,293	)	$	39,840	$	69,261	$	(28,062	)	$	41,199
Customer relationships	12 years		142,954		(51,969	)		90,985		99,290		(45,505	)		53,785
Trademarks/brand names	35 years		33,976		(9,179	)		24,797		33,448		(8,467	)		24,981
Trademarks/brand names	Indefinite		48,484		—			48,484		49,384		—			49,384
Supplier relationships	30 years		29,300		(5,014	)		24,286		29,300		(4,525	)		24,775
All other*	15 years		10,477		(7,934	)		2,543		8,440		(7,660	)		780


		$	337,324	$	(106,389	)	$	230,935	$	289,123	$	(94,219	)	$	194,904

*	At December 31, 2010 all other included in-process research and development of $0.3 million which was indefinite lived. During the second quarter of 2011, this asset was placed in service as a component of completed technology.

Based on quarter-end exchange rates, annual amortization expense is expected to approximate $23.8 million in 2011, $23.4 million in 2012, $17.6 million in 2013, $16.7 million in 2014 and $14.7 million in 2015. Identifiable intangible assets are initially recorded at fair market value at the time of acquisition using an income or cost approach.

- Definition

Discloses the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain or loss on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss. This element may be used as a single block of text to include the entire intangible asset disclosure including data and tables.

+ References+ Details

Debt

6 Months Ended

Jun. 30, 2011

Debt

Debt

5. DEBT

2016 Convertible Senior Notes

On June 15, 2011, the Company issued $230.0 million aggregate principal amount of its 1.625% Convertible Senior Notes due 2016 (the "2016 Notes"). The 2016 Notes mature on December 15, 2016, and bear interest at a rate of 1.625% per annum payable semi-annually in arrears on December 15 and June 15 of each year. The portion of the debt proceeds that was classified as equity at the time of the offering was $43.2 million, and that amount is being amortized to interest expense using the effective interest method through December 2016. The effective interest rate implicit in the liability component is 5.6%. In connection with this offering, the Company capitalized approximately $6.3 million of financing fees. At June 30, 2011, the carrying amount of the liability component was $187.2 million, the remaining unamortized discount was $42.8 million, and the principal amount outstanding was $230.0 million. The fair value of the 2016 Notes at June 30, 2011 was approximately $231.4 million.

The 2016 Notes are senior, unsecured obligations of the Company, and are convertible into cash and, if applicable, shares of its common stock based on an initial conversion rate, subject to adjustment of 17.4092 shares per $1,000 principal amount of 2016 Notes (which represents an initial conversion price of approximately $57.44 per share). The Company will satisfy any conversion of the 2016 Notes with cash up to the principal amount of the 2016 Notes pursuant to the net share settlement mechanism set forth in the indenture and, with respect to any excess conversion value, with shares of the Company's common stock. The 2016 Notes are convertible only in the following circumstances: (1) if the closing sale price of the Company's common stock exceeds 150% of the conversion price during a period as defined in the indenture; (2) if the average trading price per $1,000 principal amount of the 2016 Notes is less than or equal to 98% of the average conversion value of the 2016 Notes during a period as defined in the indenture; (3) at any time on or after June 15, 2016; or (4) if specified corporate transactions occur. The issue price of the 2016 Notes was equal to their face amount, which is also the amount holders are entitled to receive at maturity if the 2016 Notes are not converted. As of June 30, 2011, none of these conditions existed with respect to the 2016 Notes and as a result, the 2016 Notes are classified as long term.

Holders of the 2016 Notes, who convert their notes in connection with a qualifying fundamental change, as defined in the related indenture, may be entitled to a make-whole premium in the form of an increase in the conversion rate. Additionally, following the occurrence of a fundamental change, holders may require that the Company repurchase some or all of the 2016 Notes for cash at a repurchase price equal to 100% of the principal amount of the notes being repurchased, plus accrued and unpaid interest, if any.

The 2016 Notes, under the terms of the private placement agreement, are guaranteed fully by Integra LifeSciences Corporation, a subsidiary of the Company. The Notes are the Company's direct senior unsecured obligations and rank equal in right of payment to all of the Company's existing and future unsecured and unsubordinated indebtedness.

In connection with the issuance of the 2016 Notes, the Company entered into call transactions and warrant transactions, primarily with affiliates of the initial purchasers of the Notes (the "hedge participants"). The cost of the call transactions to the Company was approximately $42.9 million, representing options to buy 4.0 million shares from the hedge participants at an initial strike price of $57.44 per share, subject to customary anti-dilution adjustments. These transactions are expected to reduce the potential dilution upon conversion of the notes. The Company received approximately $28.5 million of proceeds from the warrant transactions, representing an obligation to potentially deliver 4.0 million shares to the hedge participants at an initial strike price of $70.05 per share, subject to customary anti-dilution adjustments. The earliest expiration of these warrant transactions is March 15, 2017 and they continue to expire through the 100th scheduled trading day thereafter, as defined in the indenture. The warrants could separately have a dilutive effect on the Company's earnings per share if the market price of its common stock exceeds the strike price of the warrants.

During the three and six months ended June 30, 2011, the Company recognized non-cash interest of $0.3 million and cash interest of $0.2 million for a total of $0.5 million on the 2016 Notes.

Amended and Restated Senior Credit Agreement

On August 10, 2010, the Company entered into an amended and restated credit agreement with a syndicate of lending banks (the "Senior Credit Facility") and further amended the Senior Credit Facility on June 8, 2011. The June 8, 2011 amendment increased the revolving credit component from $450.0 million to $600.0 million and eliminated the $150.0 million term loan component that existed under the original amended and restated credit agreement, allows the Company to further increase the size of the revolving credit component by an aggregate of $200.0 million with additional commitments, provides the Company with decreased borrowing rates and annual commitment fees, and provides more favorable financial covenants. The Senior Credit Facility's maturity was extended from August 10, 2015 to June 8, 2016 and is collateralized by substantially all of the assets of the Company's U.S. subsidiaries, excluding intangible assets. In connection with the June 8, 2011 amendment, the Company capitalized $1.3 million of incremental financing costs, expensed $0.4 million of incremental financing costs, and expensed $0.4 million of previously capitalized financing costs. The Senior Credit Facility is subject to various financial and negative covenants and at June 30, 2011, the Company was in compliance with all such covenants.

Borrowings under the Senior Credit Facility currently bear interest, at the Company's option, at a rate equal to (i) the Eurodollar Rate (as defined in the Senior Credit Facility, which definition has not changed) in effect from time to time plus the applicable rate (ranging from 1.00% to 1.75%) or (ii) the highest of (x) the weighted average overnight Federal funds rate, as published by the Federal Reserve Bank of New York, plus 0.5%, (y) the prime lending rate of Bank of America, N.A. or (z) the one-month Eurodollar Rate plus 1.0%. The applicable rates are based on the Company's consolidated total leverage ratio (defined as the ratio of (a) consolidated funded indebtedness less cash in excess of $40 million that is not subject to any restriction of the use or investment thereof to (b) consolidated EBITDA) at the time of the applicable borrowing.

The Company will also pay an annual commitment fee (ranging from 0.15% to 0.3%, based on the Company's consolidated total leverage ratio) on the daily amount by which the revolving credit facility exceeds the outstanding loans and letters of credit under the credit facility.

At June 30, 2011 and December 31, 2010, there was $144.4 million and $100.0 million outstanding, respectively, under the revolving credit component of the Senior Credit Facility at a weighted average interest rate of 1.5% and 2.5%, respectively. At June 30, 2011, there was approximately $455.6 million available for borrowing under the Senior Credit Facility. The fair value of outstanding borrowings under the Senior Credit Facility at June 30, 2011 was approximately $131.7 million. The Company considers the balance to be long-term in nature based on its current intent and ability to repay the borrowing outside of the next twelve-month period.

At December 31, 2010, there was $148.1 million outstanding under the term loan component of the Senior Credit Facility at an interest rate of 2.6%, and as noted above, this portion of the credit facility was eliminated and replaced with borrowings under the revolving credit component in June 2011.

2010 and 2012 Senior Convertible Notes

On June 11, 2007, the Company issued $165.0 million aggregate principal amount of its 2010 Notes and $165.0 million aggregate principal amount of its 2012 Notes (the 2010 Notes and the 2012 Notes, collectively the "Notes"). The 2010 Notes and the 2012 Notes bear interest at a rate of 2.75% per annum and 2.375% per annum, respectively, in each case payable semi-annually in arrears on December 1 and June 1 of each year. The portion of the debt proceeds that was classified as equity at the time of the offering was $16.4 million for the 2010 Notes and $30.6 million for the 2012 Notes. Those amounts are being amortized to interest expense using the effective interest method through June 2010 for the 2010 Notes, and through June 2012 for the 2012 Notes. The effective interest rate implicit in the liability component is 6.5% for the 2010 Notes and 6.8% for the 2012 Notes. The 2010 Notes were paid off in June 2010 in accordance with their terms. At June 30, 2011, the carrying amount of the liability component of the 2012 Notes was $158.5 million, the remaining unamortized discount was $6.5 million, and the principal amount outstanding was $165.0 million. At December 31, 2010, the carrying amount of the liability component of the 2012 Notes was $155.2 million, the remaining unamortized discount was $9.8 million, and the principal amount outstanding was $165.0 million. The entire carrying amount of the 2012 Notes is classified as long-term in the June 30, 2011 balance sheet as the Company has the intent and ability to settle the obligation with long-term borrowings from its Senior Credit Facility. The fair value of the 2012 Notes at June 30, 2011 was approximately $166.5 million.

The 2012 Notes are senior, unsecured obligations of the Company, and are convertible into cash and, if applicable, shares of its common stock based on an initial conversion rate, subject to adjustment, of 15.3935 shares per $1,000 principal amount of notes (which represents an initial conversion price of approximately $64.96 per share). The Company will satisfy any conversion of the 2012 Notes with cash up to the principal amount pursuant to the net share settlement mechanism set forth in the indenture and, with respect to any excess conversion value, with shares of the Company's common stock. The 2012 Notes are convertible only in the following circumstances: (1) if the closing sale price of the Company's common stock exceeds 130% of the conversion price during a period as defined in the indenture; (2) if the average trading price per $1,000 principal amount of the 2012 Notes is less than or equal to 97% of the average conversion value of the 2012 Notes during a period as defined in the indenture; (3) anytime after December 15, 2011; or (4) if specified corporate transactions occur. None of these conditions existed with respect to the 2012 Notes as of June 30, 2011. The 2012 Notes are classified as long-term based on the Company's intent and ability to settle the obligation with long-term borrowings from its Senior Credit Facility. The issue price of the 2012 Notes was equal to their face amount, which is also the amount holders are entitled to receive at maturity if the 2012 Notes are not converted.

In connection with the issuance of the 2012 Notes, the Company entered into call transactions and warrant transactions, primarily with affiliates of the initial purchasers of the Notes (the "hedge participants"). The cost of the call transactions to the Company was approximately $30.4 million, representing options to buy 2.5 million shares from the hedge participants at an initial strike price of approximately $64.96 per share, subject to customary anti-dilution adjustments. These transactions are expected to reduce the potential dilution upon conversion of the notes. The Company received approximately $12.2 million of proceeds from the warrant transactions, representing an obligation to potentially deliver 2.5 million shares to the hedge participants at an initial strike price of approximately $77.96 per share, subject to customary anti-dilution adjustments. These warrant transactions expire on various dates between August 30, 2012 and January 23, 2013 and could separately have a dilutive effect on the Company's earnings per share if the market price of its common stock exceeds the strike price of the warrants.

The interest expense components of the 2010 Notes and the 2012 Notes are as follows:


	Three Months Ended June 30,				Six Months Ended June 30,
	2011		2010		2011		2010
	(amounts in thousands)
2010 Notes:
Non-cash interest	$	–	$	480	$	–	$	1,190
Cash Interest		–		357		–		830

Total	$	–	$	837	$	–	$	2,020

2012 Notes:
Non-cash interest	$	1,698	$	1,586	$	3,367	$	3,146
Cash Interest		980		980		1,959		1,959

Total	$	2,678	$	2,566	$	5,326	$	5,105

Derivative Instruments

6 Months Ended

Jun. 30, 2011

Derivative Instruments

Derivative Instruments

6. DERIVATIVE INSTRUMENTS

Interest Rate Hedging

The Company's interest rate risk relates to U.S. dollar denominated variable LIBOR interest rate borrowings. The Company uses an interest rate swap derivative instrument entered into on August 10, 2010 with an effective date of December 31, 2010 to manage its earnings and cash flow exposure to changes in interest rates by converting a portion of its floating-rate debt into fixed-rate debt beginning on December 31, 2010. This interest rate swap expires on August 10, 2015.

The Company designates this derivative instrument as a cash flow hedge. The Company records the effective portion of any change in the fair value of a derivative instrument designated as a cash flow hedge as unrealized gains or losses in accumulated other comprehensive income ("AOCI"), net of tax, until the hedged item affects earnings, at which point the effective portion of any gain or loss will be reclassified to earnings. If the hedged cash flow does not occur, or if it becomes probable that it will not occur, the Company will reclassify the amount of any gain or loss on the related cash flow hedge to interest expense at that time.

The Company expects that approximately $2.1 million of pre-tax losses recorded as net in AOCI related to the interest rate hedge could be reclassified to earnings within the next twelve months.

Foreign Currency Hedging

From time to time the Company enters into foreign currency hedge contracts intended to protect the U.S. dollar value of certain forecasted foreign currency denominated transactions. There were no foreign currency hedge contracts outstanding as of June 30, 2011 or December 31, 2010. The Company records the effective portion of any change in the fair value of foreign currency cash flow hedges in AOCI, net of tax, until the hedged item affects earnings. Once the related hedged item affects earnings, the Company reclassifies the effective portion of any related unrealized gain or loss on the foreign currency cash flow hedge to earnings. If the hedged forecasted transaction does not occur, or if it becomes probable that it will not occur, the Company will reclassify the amount of any gain or loss on the related cash flow hedge to earnings at that time.

The success of the Company's hedging program depends, in part, on forecasts of certain activity denominated in euros. The Company may experience unanticipated currency exchange gains or losses to the extent that there are differences between forecasted and actual activity during periods of currency volatility. In addition, changes in currency exchange rates related to any unhedged transactions may affect its earnings and cash flows.

Counterparty Credit Risk

The Company manages its concentration of counterparty credit risk on its derivative instruments by limiting acceptable counterparties to a group of major financial institutions with investment grade credit ratings, and by actively monitoring their credit ratings and outstanding positions on an ongoing basis. Therefore, the Company considers the credit risk of the counterparties to be low. Furthermore, none of the Company's derivative transactions is subject to collateral or other security arrangements, and none contains provisions that depend upon the Company's credit ratings from any credit rating agency.

Fair Value of Derivative Instruments

The Company has classified all of its derivative instruments within Level 2 of the fair value hierarchy because observable inputs are available for substantially the full term of the derivative instruments. The following table summarizes the fair value, notional amounts presented in U.S. dollars, and presentation in the consolidated balance sheet for derivatives designated as hedging instruments as of June 30, 2011 and December 31, 2010:


	Fair Value as of
	June 30,		December 31,
Location on Balance Sheet (a):	2011		2010
	(In thousands)

Derivative Assets:
Interest rate swap — Other assets (b)	$	196	$	1,825


Derivative Liabilities:
Interest rate swap — Accrued expenses and other current liabilities (b)	$	2,103	$	2,095

(a)	The Company classifies derivative assets and liabilities as current based on the cash flows expected to be incurred within the following 12 months.

(b)	At June 30, 2011 and December 31, 2010, the notional amount related to the Company's sole interest rate swap was $144.4 million and $148.1 million, respectively. In the subsequent twelve months, the Company expects to reduce these amounts by $10.3 million and $8.4 million, respectively.

The following presents the effect of derivative instruments designated as cash flow hedges on the accompanying consolidated statements of operations during the three and six months ended June 30, 2011 and 2010:


	Amount of Gain (Loss) Recognized in AOCI- Effective Portion			Amount of Gain (Loss) Reclassified from AOCI Into Earnings- Effective Portion			Location in Statements of Operations
	(In thousands)

Three Months Ended June 30, 2011
Interest rate swap	$	(2,958	)	$	(570	)	Interest (expense)


Three Months Ended June 30, 2010
Currency hedge contracts	$	(1,018	)	$	(1,009	)	Other income (expense)


Six Months Ended June 30, 2011
Interest rate swap	$	(2,781	)	$	(1,143	)	Interest (expense)


Six Months Ended June 30, 2010
Currency hedge contracts	$	(1,734	)	$	(1,718	)	Other income (expense)

The Company recognized no gains or losses resulting from ineffectiveness of cash flow hedges during the three and six months ended June 30, 2011 and 2010.

Stock-Based Compensation	6 Months Ended
Stock-Based Compensation	Jun. 30, 2011
Stock-Based Compensation
Stock-Based Compensation	7. STOCK-BASED COMPENSATION As of June 30, 2011, the Company had stock options, restricted stock awards, performance stock awards, contract stock awards and restricted stock unit awards outstanding under six plans, the 1996 Incentive Stock Option and Non-Qualified Stock Option Plan (the "1996 Plan"), the 1998 Stock Option Plan (the "1998 Plan"), the 1999 Stock Option Plan (the "1999 Plan"), the 2000 Equity Incentive Plan (the "2000 Plan"), the 2001 Equity Incentive Plan (the "2001 Plan"), and the 2003 Equity Incentive Plan (the "2003 Plan," and collectively, the "Plans"). No new awards may be granted under the 1996 Plan, the 1998 Plan, the 1999 Plan and the 2000 Plan. Stock options issued under the Plans become exercisable over specified periods, generally within four years from the date of grant for officers, directors and employees, and generally expire six years from the grant date for employees and from six to ten years for directors and certain executive officers. Restricted stock issued under the Plans vests over specified periods, generally three years after the date of grant. Stock Options The Company granted approximately 34,000 and 59,000 stock options during the six months ended June 30, 2011 and June 30, 2010, respectively. As of June 30, 2011, there were approximately $1.3 million of total unrecognized compensation costs related to unvested stock options. These costs are expected to be recognized over a weighted-average period of approximately 2 years. The Company received net proceeds of $3.3 million and $4.6 million from stock option exercises for the six months ended June 30, 2011 and 2010, respectively. Awards of Restricted Stock, Performance Stock and Contract Stock Performance stock awards have performance features associated with them. Performance stock, restricted stock and contract stock awards generally have requisite service periods of three years. The Company expenses the fair value of these awards on a straight-line basis over the vesting period or requisite service period, whichever is shorter. As of June 30, 2011, there were approximately $13.1 million of total unrecognized compensation costs related to unvested awards. The Company expects to recognize these costs over a weighted-average period of approximately two years. On May 17, 2011, in connection with the extension of the employment agreement with the chief executive officer, the Company provided a grant of 165,000 contract stock/stock units ("SUs"). As the SUs vested at the grant date, the Company recognized a charge of approximately $8.4 million upon issuance, which was included in selling, general and administrative expenses. The Company has no formal policy related to the repurchase of shares for the purpose of satisfying stock-based compensation obligations. The Company also maintains an Employee Stock Purchase Plan (the "ESPP"), which provides eligible employees with the opportunity to acquire shares of common stock at periodic intervals by means of accumulated payroll deductions. The ESPP is a non-compensatory plan based on its terms.

Treasury Stock

6 Months Ended

Jun. 30, 2011

Treasury Stock

Treasury Stock

8. TREASURY STOCK

On October 29, 2010, the Company's Board of Directors authorized the Company to repurchase shares of the Company's common stock for an aggregate purchase price not to exceed $75.0 million through December 31, 2012. Shares may be purchased either in the open market or in privately negotiated transactions. As of June 30, 2011, there remained $55.5 million available for share repurchases under this authorization. In addition to the authorization above, on June 3, 2011, the Company's Board of Directors separately authorized the Company to repurchase shares of common stock from the proceeds of the 2016 Notes in connection with that offering. The following table sets forth the Company's treasury stock activity:


	Six Months Ended June 30, 2011
	$		# of Shares
	(In thousands)
Shares repurchased in the open market in connection with the Board approved buyback program	$	19,439		408
Shares repurchased in connection with the issuance of the 2016 Notes		37,570		805


Total	$	57,009		1,213

Retirement Benefit Plans

6 Months Ended

Jun. 30, 2011

Retirement Benefit Plans

Retirement Benefit Plans

9. RETIREMENT BENEFIT PLANS

The Company maintains defined benefit pension plans that cover employees in its manufacturing plants located in Andover, United Kingdom (the "UK Plan") and Tuttlingen, Germany (the "Germany Plan"). The Company closed the Tuttlingen, Germany plant in December 2005. The Company did not terminate the Germany Plan and the Company remains obligated for the accrued pension benefits related to this plan. The plans cover certain current and former employees.

Effective March 31, 2011, the Company froze the benefits due to the participants of the UK Plan in their entirety; this curtailment resulted in a $0.3 million reduction in the projected benefit obligations which the Company recorded on that date. The Company recorded the entire curtailment gain as an offset to the unrecognized net actuarial loss in accumulated other comprehensive income; therefore, this gain had no impact on the condensed consolidated statements of operations.

Net periodic benefit costs for the Company's defined benefit pension plans included the following amounts (in thousands):


	Three Months Ended June 30,						Six Months Ended June 30,
	2011			2010			2011			2010
Service cost	$	26		$	26		$	53		$	53
Interest cost		169			155			334			313
Expected return on plan assets		(149	)		(119	)		(295	)		(244	)
Recognized net actuarial loss		—			36			—			74


Net period benefit cost	$	46		$	98		$	92		$	196

The Company made $0.4 million and $0.5 million of contributions to its defined benefit pension plans during the six months ended June 30, 2011 and 2010, respectively.

- Definition

Description containing the entire pension and other postretirement benefits disclosure as a single block of text.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 158

-Paragraph 7, 21, 22

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 132R

-Paragraph 5, 6, 7, 8

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 132R

-Paragraph 8

-Subparagraph m

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 106

-Paragraph 518

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 87

-Paragraph 264

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 132R

-Paragraph 5

-Subparagraph b

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 132R

-Paragraph 5

-Subparagraph a

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 132R

-Paragraph 5

-Subparagraph h

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 132R

-Paragraph 5

-Subparagraph q

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Staff Position (FSP)

-Number FAS106-2

-Paragraph 20, 21, 22

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 03-2

-Paragraph 8

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 30

-Paragraph 26

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Implementation Guide (Q and A)

-Number FAS88

-Paragraph 63

+ Details

Income Taxes

6 Months Ended

Jun. 30, 2011

Income Taxes

Income Taxes

10. Income Taxes

The following table provides a summary of the Company's effective tax rate:


	Three Months Ended June 30,
	2011			2010

Reported tax rate		65.0	%		28.1	%

	Six Months Ended June 30,
	2011			2010

Reported tax rate		27.6	%		24.8	%

The Company's effective income tax rates for the three months ended June 30, 2011 and 2010 were 65.0% and 28.1%, respectively. Income tax expense for the three months ended June 30, 2011 included a $1.7 million correction to a deferred tax asset relating to 2009. The correction was not material to 2009 or to the expected results for the full year 2011, but represented a sizable adjustment to the tax expense recorded in the quarter. In addition, a tax law change in the State of New Jersey, effective June 30, 2011, resulted in an adjustment to certain deferred tax assets, which increased tax expense by $0.7 million. Further, the Company's projection of full year income decreased significantly, especially in the United States because of certain costs and expenses recorded in the second quarter and the projection of similar costs and expenses for the remainder of the year. This change in estimate of the expected full year tax rate resulted in a year-to-date reduction of income tax expense recorded in the quarter. All of these items resulted in the reported effective tax rate for the three months ended June 30, 2011 to be 65.0%.

The Company's effective income tax rates for the six months ended June 30, 2011 and 2010 were 27.6% and 24.8%, respectively. The income tax expense for the six months ended June 30, 2011 includes additional tax expense related to a $1.7 million correction to a deferred tax asset relating to 2009 that was recorded during the six-month period. This increase is partially offset because the Tax Relief, Unemployment Insurance and Job Creation Act of 2010 was passed during the fourth quarter of 2010, and had the effect of lowering the tax rate used to determine the tax provision for the second quarter of 2011 versus the rate that was in effect for the second quarter of 2010. Additionally, during the same period last year, we recorded a reversal of $2.3 million of accruals for uncertain tax positions resulting from matters which were considered effectively settled and the expiration of the statute of limitations for certain matters, which further lowered our effective tax rate for the prior-year period. Further, the Company's projection of full year income decreased significantly, especially in the United States because of certain costs and expenses recorded in the second quarter and the projection of similar costs and expenses for the remainder of the year. This change in estimate of the expected full year tax rate resulted in a year-to-date reduction of income tax expense recorded during the six-month period.

Net Income Per Share

6 Months Ended

Jun. 30, 2011

Net Income Per Share

Net Income Per Share

11. NET INCOME PER SHARE

Certain of the Company's unvested restricted share units contain rights to receive nonforfeitable dividends, and thus, are participating securities requiring the two-class method of computing earnings per share. The participating securities had an insignificant impact on the calculation of earnings per share (impacts the rounding by less than $0.01 per share) on all of the periods presented; therefore, the Company does not present the full calculation below.

Basic and diluted net income per share was as follows (in thousands, except per share amounts):


	Three Months Ended June 30,				Six Months Ended June 30,
	2011		2010		2011		2010
Basic net income per share:
Net income	$	699	$	15,157	$	12,186	$	30,379
Weighted average common shares outstanding		29,556		29,855		29,559		29,672
Basic net income per common share	$	0.02	$	0.51	$	0.41	$	1.02

Diluted net income per share:
Net income	$	699	$	15,157	$	12,186	$	30,379
Weighted average common shares outstanding — Basic		29,556		29,855		29,559		29,672
Effect of dilutive securities:
Stock options and restricted stock		622		544		595		610


Weighted average common shares for diluted earnings per share		30,178		30,399		30,154		30,282

Diluted net income per common share	$	0.02	$	0.50	$	0.40	$	1.00

At June 30, 2011 and 2010 the Company had 1.5 million and 1.9 million of outstanding stock options, respectively. The Company also has warrants outstanding relating to its 2016 Notes and 2012 Notes. Stock options, restricted stock and warrants are included in the diluted earnings per share calculation using the treasury stock method, unless the effect of including the stock options would be anti-dilutive. For the three months ended June 30, 2011 and 2010, 0.1 million and 0.7 million anti-dilutive stock options, respectively, were excluded from the diluted earnings per share calculation. For the six months ended June 30, 2011 and 2010, 0.2 million and 0.7 million anti-dilutive stock options, respectively, were excluded from the diluted earnings per share calculation. As the strike price of the warrants exceeded the Company's average stock price for the period, the warrants are anti-dilutive and the entire number of warrants was also excluded from the diluted earnings per share calculation.

Comprehensive (Loss) Income

6 Months Ended

Jun. 30, 2011

Comprehensive (Loss) Income

Comprehensive (Loss) Income

12. COMPREHENSIVE (LOSS) INCOME

Comprehensive (loss) income was as follows (in thousands):


	Three Months Ended June 30,						Six Months Ended June 30,
	2011			2010			2011			2010
Net Income	$	699		$	15,157		$	12,186		$	30,379
Foreign currency translation adjustment		4,934			(16,704	)		18,400			(27,933	)
Change in unrealized gain on derivatives, net of tax		(1,361	)		(5	)		(933	)		(11	)
Pension liability adjustment, net of tax		(77	)		—			185			—


Comprehensive income (loss)	$	4,195		$	(1,552	)	$	29,838		$	2,435

- Definition

This label may include the following: 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income. Components of comprehensive income include: (1) foreign currency translation adjustments; (2) gains and losses on foreign currency transactions that are designated as, and are effective as, economic hedges of a net investment in a foreign entity; (3) gains and losses on intercompany foreign currency transactions that are of a long-term-investment nature, when the entities to the transaction are consolidated, combined, or accounted for by the equity method in the reporting enterprise's financial statements; (4) change in the market value of a futures contract that qualifies as a hedge of an asset reported at fair value; (5) unrealized holding gains and losses on available-for-sale securities and that resulting from transfers of debt securities from the held-to-maturity category to the available-for-sale category; (6) a net loss recognized as an additional pension liability not yet recognized as net periodic pension cost; and (7) the net gain or loss and net prior service cost or credit for pension plans and other postretirement benefit plans.

+ References+ Details

Segment And Geographic Information

6 Months Ended

Jun. 30, 2011

Segment And Geographic Information

Segment And Geographic Information

13. SEGMENT AND GEOGRAPHIC INFORMATION

The Company's chief operating decision maker reviews financial results and manages the business on an aggregate basis. Therefore, the Company presents financial results in a single reporting segment - the development, manufacture and distribution of medical devices.

Revenue consisted of the following (in thousands):


	Three Months Ended June 30,				Six Months Ended June 30,
	2011		2010		2011		2010
Orthopedics	$	80,579	$	72,819	$	152,813	$	143,006
Neurosurgery		72,102		66,306		140,460		131,080
Instruments		40,648		39,470		81,097		77,207


Total revenues	$	193,329	$	178,595	$	374,370	$	351,293

The Company attributes revenues to geographic areas based on the location of the customer. We summarize total revenues by major geographic area below (in thousands):


	Three Months Ended June 30,				Six Months Ended June 30,
	2011		2010		2011		2010
United States	$	144,872	$	138,760	$	278,172	$	268,123
Europe		25,209		20,076		50,296		44,228
Asia Pacific		11,625		9,174		22,372		18,411
Other Foreign		11,623		10,585		23,530		20,531


Total revenues	$	193,329	$	178,595	$	374,370	$	351,293

Commitments And Contingencies	6 Months Ended
Commitments And Contingencies	Jun. 30, 2011
Commitments And Contingencies
Commitment And Contingencies	14. COMMITMENTS AND CONTINGENCIES In consideration for certain technology, manufacturing, distribution and selling rights and licenses granted to the Company, the Company has agreed to pay royalties on sales of certain products that we sell. The royalty payments that the Company made under these agreements were not significant for any of the periods presented. The Company has settled, or has pending against it, various other lawsuits, claims and proceedings. We describe the most significant of these below. In January 2010, the Company received a notice from the seller's representative of the former Theken companies of a disagreement in the calculation of "trade sales" used in calculating a revenue performance payment that the Company made in November 2009 related to the first performance year that ended September 30, 2009. The notice alleged that the Company owed an additional $6.7 million, and the Company recorded an accrual of $3.4 million for the settlement at that time. In January 2011, the Company received a notice from the seller's representative that the alleged amount owed had been reduced to $5.7 million, and in June 2011 the Company and the seller agreed to settle the matter for $4.6 million. An accrual for an additional $1.2 million has been recorded at June 30, 2011 – for a total accrual of $4.6 million. There are no amounts due under the asset purchase agreement for the second performance year that ended September 30, 2010. The Company has various product liability claims pending against it for which it currently has accruals totaling $4.8 million recorded in the financial statements. The Company's insurance policies cover these matters and the Company has recorded a corresponding receivable. Therefore, there is no impact on the Company's consolidated statements of operations. In addition to these matters, the Company is subject to various claims, lawsuits and proceedings in the ordinary course of its business, including claims by current or former employees, distributors and competitors and with respect to its products. In the opinion of management, such claims are either adequately covered by insurance or otherwise indemnified, or are not expected, individually or in the aggregate, to result in a material adverse effect on the Company's financial condition. However, it is possible that these contingencies could materially affect its results of operations, financial position and cash flows in a particular period. The Company accrues for loss contingencies when it is deemed probable that a loss has been incurred and that loss is estimable. The amounts accrued are based on the full amount of the estimated loss before considering insurance proceeds, and do not include an estimate for legal fees expected to be incurred in connection with the loss contingency. The Company consistently accrues legal fees expected to be incurred in connection with loss contingencies as a period cost as outside counsel incurs those fees.

Basis Of Presentation (Policy)	6 Months Ended
Basis Of Presentation (Policy)	Jun. 30, 2011
Basis Of Presentation
General	The terms "we," "our," "us," "Company" and "Integra" refer to Integra LifeSciences Holdings Corporation, a Delaware corporation, and its subsidiaries unless the context suggests otherwise. In the opinion of management, the June 30, 2011 unaudited condensed consolidated financial statements contain all adjustments (consisting only of normal recurring adjustments) necessary for a fair statement of the financial position, results of operations and cash flows of the Company. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. These unaudited condensed consolidated financial statements should be read in conjunction with the Company's consolidated financial statements for the year ended December 31, 2010 included in the Company's Annual Report on Form 10-K. The December 31, 2010 condensed consolidated balance sheet was derived from audited financial statements but does not include all disclosures required by accounting principles generally accepted in the United States. Operating results for the three- and six-month periods ended June 30, 2011 are not necessarily indicative of the results to be expected for the entire year. The preparation of consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amount of assets and liabilities, the disclosure of contingent liabilities, and the reported amounts of revenues and expenses. Significant estimates affecting amounts reported or disclosed in the consolidated financial statements include allowances for doubtful accounts receivable and sales returns and allowances, net realizable value of inventories, valuation of intangible assets including in-process research and development, amortization periods for acquired intangible assets, discount rates and estimated projected cash flows used to value and test impairments of long-lived assets and goodwill, estimates of projected cash flows and depreciation and amortization periods for long-lived assets, computation of taxes, valuation allowances recorded against deferred tax assets, the valuation of stock-based compensation, valuation of pension assets and liabilities, valuation of derivative instruments, valuation of the equity component of convertible debt instruments, and loss contingencies. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the current circumstances. Actual results could differ from these estimates. Certain amounts from the prior year's financial statements have been reclassified in order to conform to the current year's presentation.
Recently Issued Accounting Standards	On June 16, 2011 the Financial Accounting Standards Board issued Accounting Standards Update No. 2011-05, Presentation of Comprehensive Income; this standard eliminates the option to report other comprehensive income and its components in the statement of changes in equity. The Company can elect to present items of net income and other comprehensive income in one continuous statement, or in two consecutive statements. Each component of net income and each component of other comprehensive income, together with totals for comprehensive income and its two parts – net income and other comprehensive income – would need to be displayed under either alternative, and the statements would need to be presented with equal prominence as the other primary financial statements. This standard does not change: 1) the items that constitute net income and other comprehensive income, 2) when an item of other comprehensive income must be reclassified to net income, or 3) the computation for earnings-per-share - which will continue to be based on net income. This standard is effective for fiscal years beginning after December 15, 2011, and the Company has not yet determined which method it will elect upon adoption. On May 12, 2011 the Financial Accounting Standards Board issued Accounting Standards Update No. 2011-04 - Fair Value Measurement (Topic 820): Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRS. This standard merges many aspects of fair value measurement guidance by amending U.S. GAAP and creating a new standard under International Financial Reporting Standards. The primary changes to U.S. GAAP include: 1) clarifying the valuation premise of highest and best use, 2) clarifying how portfolios of financial instruments are measured, 3) clarifying the use of blockage factors and other premiums and discounts, and 4) increasing the disclosure requirements in a number of circumstances. This standard is effective for fiscal years beginning after December 15, 2011, and the Company believes the standard will not have a material impact on the Company's results.

- Definition

Describes an entity's accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. An entity also may describe its accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.

+ References+ Details

Business And Asset Acquisitions (Tables) (SeaSpine [Member])

6 Months Ended

Jun. 30, 2011

SeaSpine [Member]

Final Purchase Price Of Net Assets Acquired


Cash	$	201
Inventory		14,900
Accounts receivable		7,608
Other current assets		623
Property, plant and equipment		9,177
Deferred tax asset—long term		302
Intangible assets:			Wtd. Avg. Life:
Technology		3,000	8 years
Customer relationships		41,200	13 years
Non-compete agreements		1,900	4 years
Brand name		300	1 year
Goodwill		14,897

Total assets acquired		94,108
Accounts payable and other liabilities		5,108

Net assets acquired	$	89,000

Inventories (Tables)

6 Months Ended

Jun. 30, 2011

Inventories

Inventories


	June 30,		December 31,
	2011		2010
	(In thousands)
Finished goods	$	109,065	$	87,508
Work-in process		35,444		31,536
Raw materials		29,951		27,884

	$	174,460	$	146,928

Goodwill And Other Intangible Assets (Tables)

6 Months Ended

Jun. 30, 2011

Goodwill And Other Intangible Assets

Changes In The Carrying Amount Of Goodwill


Goodwill	$	261,928
Accumulated impairment losses		—


Goodwill at December 31, 2010		261,928

SeaSpine acquisition		14,897
Integra Spine earnout		1,200
Integra Neurosciences Pty Ltd. earnout		1,059
Foreign currency translation		6,292


Goodwill at June 30, 2011	$	285,376

Components Of The Company's Identifiable Intangible Assets


	Weighted Average Life	June 30, 2011							December 31, 2010
	Weighted Average Life	Cost		Accumulated Amortization			Net		Cost		Accumulated Amortization			Net
Completed technology	12 years	$	72,133	$	(32,293	)	$	39,840	$	69,261	$	(28,062	)	$	41,199
Customer relationships	12 years		142,954		(51,969	)		90,985		99,290		(45,505	)		53,785
Trademarks/brand names	35 years		33,976		(9,179	)		24,797		33,448		(8,467	)		24,981
Trademarks/brand names	Indefinite		48,484		—			48,484		49,384		—			49,384
Supplier relationships	30 years		29,300		(5,014	)		24,286		29,300		(4,525	)		24,775
All other*	15 years		10,477		(7,934	)		2,543		8,440		(7,660	)		780


		$	337,324	$	(106,389	)	$	230,935	$	289,123	$	(94,219	)	$	194,904

Debt (Tables)

6 Months Ended

Jun. 30, 2011

Debt

Components Of Interest Expense


	Three Months Ended June 30,				Six Months Ended June 30,
	2011		2010		2011		2010
	(amounts in thousands)
2010 Notes:
Non-cash interest	$	–	$	480	$	–	$	1,190
Cash Interest		–		357		–		830

Total	$	–	$	837	$	–	$	2,020

2012 Notes:
Non-cash interest	$	1,698	$	1,586	$	3,367	$	3,146
Cash Interest		980		980		1,959		1,959

Total	$	2,678	$	2,566	$	5,326	$	5,105

Derivative Instruments (Tables)

6 Months Ended

Jun. 30, 2011

Derivative Instruments

Summary Of Fair Value In Balance Sheet For Derivatives Designated As Hedging Instruments


	Fair Value as of
	June 30,		December 31,
Location on Balance Sheet (a):	2011		2010
	(In thousands)

Derivative Assets:
Interest rate swap — Other assets (b)	$	196	$	1,825


Derivative Liabilities:
Interest rate swap — Accrued expenses and other current liabilities (b)	$	2,103	$	2,095

(a)	The Company classifies derivative assets and liabilities as current based on the cash flows expected to be incurred within the following 12 months.

(b)	At June 30, 2011 and December 31, 2010, the notional amount related to the Company's sole interest rate swap was $144.4 million and $148.1 million, respectively. In the subsequent twelve months, the Company expects to reduce these amounts by $10.3 million and $8.4 million, respectively.

Effect Of Derivative Instruments Designated As Cash Flow Hedges On Statements Of Operations


	Amount of Gain (Loss) Recognized in AOCI- Effective Portion			Amount of Gain (Loss) Reclassified from AOCI Into Earnings- Effective Portion			Location in Statements of Operations
	(In thousands)

Three Months Ended June 30, 2011
Interest rate swap	$	(2,958	)	$	(570	)	Interest (expense)


Three Months Ended June 30, 2010
Currency hedge contracts	$	(1,018	)	$	(1,009	)	Other income (expense)


Six Months Ended June 30, 2011
Interest rate swap	$	(2,781	)	$	(1,143	)	Interest (expense)


Six Months Ended June 30, 2010
Currency hedge contracts	$	(1,734	)	$	(1,718	)	Other income (expense)

Treasury Stock (Tables)

6 Months Ended

Jun. 30, 2011

Treasury Stock

Treasury Stock Activity


	Six Months Ended June 30, 2011
	$		# of Shares
	(In thousands)
Shares repurchased in the open market in connection with the Board approved buyback program	$	19,439		408
Shares repurchased in connection with the issuance of the 2016 Notes		37,570		805


Total	$	57,009		1,213

Retirement Benefit Plans (Tables)

6 Months Ended

Jun. 30, 2011

Retirement Benefit Plans

Defined Benefit Pension Plans


	Three Months Ended June 30,						Six Months Ended June 30,
	2011			2010			2011			2010
Service cost	$	26		$	26		$	53		$	53
Interest cost		169			155			334			313
Expected return on plan assets		(149	)		(119	)		(295	)		(244	)
Recognized net actuarial loss		—			36			—			74


Net period benefit cost	$	46		$	98		$	92		$	196

Net Income Per Share (Tables)

6 Months Ended

Jun. 30, 2011

Net Income Per Share

Basic And Diluted Net Income Per Share


	Three Months Ended June 30,				Six Months Ended June 30,
	2011		2010		2011		2010
Basic net income per share:
Net income	$	699	$	15,157	$	12,186	$	30,379
Weighted average common shares outstanding		29,556		29,855		29,559		29,672
Basic net income per common share	$	0.02	$	0.51	$	0.41	$	1.02

Diluted net income per share:
Net income	$	699	$	15,157	$	12,186	$	30,379
Weighted average common shares outstanding — Basic		29,556		29,855		29,559		29,672
Effect of dilutive securities:
Stock options and restricted stock		622		544		595		610


Weighted average common shares for diluted earnings per share		30,178		30,399		30,154		30,282

Diluted net income per common share	$	0.02	$	0.50	$	0.40	$	1.00

Comprehensive (Loss) Income (Tables)

6 Months Ended

Jun. 30, 2011

Comprehensive (Loss) Income

Comprehensive (Loss) Income


	Three Months Ended June 30,						Six Months Ended June 30,
	2011			2010			2011			2010
Net Income	$	699		$	15,157		$	12,186		$	30,379
Foreign currency translation adjustment		4,934			(16,704	)		18,400			(27,933	)
Change in unrealized gain on derivatives, net of tax		(1,361	)		(5	)		(933	)		(11	)
Pension liability adjustment, net of tax		(77	)		—			185			—


Comprehensive income (loss)	$	4,195		$	(1,552	)	$	29,838		$	2,435

Segment And Geographic Information (Tables)

6 Months Ended

Jun. 30, 2011

Segment And Geographic Information

Revenues By Market Category


	Three Months Ended June 30,				Six Months Ended June 30,
	2011		2010		2011		2010
Orthopedics	$	80,579	$	72,819	$	152,813	$	143,006
Neurosurgery		72,102		66,306		140,460		131,080
Instruments		40,648		39,470		81,097		77,207


Total revenues	$	193,329	$	178,595	$	374,370	$	351,293

Total Revenue By Geographic Area


	Three Months Ended June 30,				Six Months Ended June 30,
	2011		2010		2011		2010
United States	$	144,872	$	138,760	$	278,172	$	268,123
Europe		25,209		20,076		50,296		44,228
Asia Pacific		11,625		9,174		22,372		18,411
Other Foreign		11,623		10,585		23,530		20,531


Total revenues	$	193,329	$	178,595	$	374,370	$	351,293

Basis Of Presentation (Details) (USD $) In Millions, except Share data, unless otherwise specified	6 Months Ended
	Jun. 30, 2010
Basis Of Presentation
Stock options exercised	282,086
Number of shares of Company stock tendered	73,546
Fair market value of shares tendered to the Company	$ 3.1

Business And Asset Acquisitions (Narrative) (Details) In Millions, unless otherwise specified	6 Months Ended	1 Months Ended				6 Months Ended
	Jun. 30, 2011 USD ($)	Dec. 31, 2010 Integra Neurosciences Pty Ltd. [Member] USD ($)	Dec. 31, 2010 Integra Neurosciences Pty Ltd. [Member] AUD	Nov. 30, 2009 Integra Neurosciences Pty Ltd. [Member] USD ($)	Nov. 30, 2009 Integra Neurosciences Pty Ltd. [Member] AUD	Jun. 30, 2011 Integra Neurosciences Pty Ltd. [Member] USD ($)	Jun. 30, 2011 Integra Neurosciences Pty Ltd. [Member] AUD	Oct. 31, 2008 Integra Neurosciences Pty Ltd. [Member] USD ($)	Oct. 31, 2008 Integra Neurosciences Pty Ltd. [Member] AUD	May 23, 2011 SeaSpine [Member] USD ($)	Nov. 30, 2009 Theken [Member] USD ($)	Aug. 31, 2008 Theken [Member] USD ($)
Company acquired in cash								$ 4.0	6.0	$ 89.0		$ 75.0
Working capital and indemnification holdback										8.0
Acquisitions expenses and working capital adjustments								0.3
Maximum future payments based on performance								2.1	3.1			125.0
Acquisition expenses												2.4
Working capital adjustments due to acquisition												3.9
Year 1 revenue performance obligation											52.0
Business acquisition contingent consideration cash payment		1.0	1.0	0.9	1.0	1.1	1.0
Accrued additional for disputed settlement amount	$ 4.6

Business And Asset Acquisitions (Final Purchase Price Of Net Assets Acquired) (Details) (USD $) In Thousands, unless otherwise specified	6 Months Ended
	Jun. 30, 2011
Technology [Member]
Weighted average life in years	8
Customer Relationships [Member]
Weighted average life in years	13
Non-Compete Agreements [Member]
Weighted average life in years	4
Brand Name [Member]
Weighted average life in years	1
SeaSpine [Member]
Cash	$ 201
Inventory	14,900
Accounts receivable	7,608
Other current assets	623
Property, plant and equipment	9,177
Deferred tax asset-long term	302
Goodwill	14,897
Total assets acquired	94,108
Accounts payable and other current liabilities	5,108
Net assets acquired	89,000
SeaSpine [Member] \| Technology [Member]
Intangible assets	3,000
SeaSpine [Member] \| Customer Relationships [Member]
Intangible assets	41,200
SeaSpine [Member] \| Non-Compete Agreements [Member]
Intangible assets	1,900
SeaSpine [Member] \| Brand Name [Member]
Intangible assets	$ 300

Inventories (Details) (USD $) In Thousands, unless otherwise specified	Jun. 30, 2011	Dec. 31, 2010
Inventories
Finished goods	$ 109,065	$ 87,508
Work-in process	35,444	31,536
Raw materials	29,951	27,884
Inventories, net	$ 174,460	$ 146,928

Goodwill And Other Intangible Assets (Narrative) (Details) (USD $) In Millions, unless otherwise specified	6 Months Ended			3 Months Ended
	Jun. 30, 2011	Jun. 30, 2011 Trademarks/ Brand Names [Member]	Jun. 30, 2011 Technology [Member]	Jun. 30, 2011 Brand Name [Member]
Impairment charge		$ 0.2	$ 1.6	$ 0.9
Annual amortization expense expected to approximate in 2011	23.8
Annual amortization expense expected to approximate in 2012	23.4
Annual amortization expense expected to approximate in 2013	17.6
Annual amortization expense expected to approximate in 2014	16.7
Annual amortization expense expected to approximate in 2015	$ 14.7

Goodwill And Other Intangible Assets (Changes In The Carrying Amount Of Goodwill) (Details) (USD $) In Thousands, unless otherwise specified	6 Months Ended
	Jun. 30, 2011
Goodwill	$ 261,928
Accumulated impairment losses
Goodwill at December 31, 2010	261,928
Foreign currency translation	6,292
Goodwill at June 30, 2011	285,376
SeaSpine [Member]
goodwill acquired during the period	14,897
Integra Spine [Member]
goodwill acquired during the period	1,200
Integra Neurosciences Pty Ltd. [Member]
goodwill acquired during the period	$ 1,059

Goodwill And Other Intangible Assets (Components Of The Company's Identifiable Intangible Assets) (Details) (USD $)

6 Months Ended

Jun. 30, 2011

Dec. 31, 2010

Cost

$ 337,324,000

$ 289,123,000

Accumulated Amortization

(106,389,000)

(94,219,000)

Net

230,935,000

194,904,000

All other included in-process research and development which is indefinite lived

300,000

Completed Technology [Member]

Weighted Average Life

12 years

Cost

72,133,000

69,261,000

Accumulated Amortization

(32,293,000)

(28,062,000)

Net

39,840,000

41,199,000

Customer Relationships [Member]

Weighted Average Life

12 years

Cost

142,954,000

99,290,000

Accumulated Amortization

(51,969,000)

(45,505,000)

Net

90,985,000

53,785,000

Trademarks/ Brand Names [Member]

Weighted Average Life

35 years

Cost

33,976,000

33,448,000

Accumulated Amortization

(9,179,000)

(8,467,000)

Net

24,797,000

24,981,000

Trademarks /Brand Names Indefinite [Member]

Weighted Average Life

Indefinite

Cost

48,484,000

49,384,000

Accumulated Amortization

Net

48,484,000

49,384,000

Supplier Relationships [Member]

Weighted Average Life

30 years

Cost

29,300,000

Accumulated Amortization

(5,014,000)

(4,525,000)

Net

24,286,000

24,775,000

All Other [Member]

Weighted Average Life

15 years

^[1]

Cost

10,477,000

^[1]

8,440,000

^[1]

Accumulated Amortization

(7,934,000)

^[1]

(7,660,000)

^[1]

Net

$ 2,543,000

^[1]

$ 780,000

^[1]

[1]	At December 31, 2010 all other included in-process research and development of $0.3 million which was indefinite lived. During the second quarter of 2011, this asset was placed in service as a component of completed technology.

Debt (Narrative) (Details) (USD $)			6 Months Ended	12 Months Ended	6 Months Ended			0 Months Ended		6 Months Ended		3 Months Ended	6 Months Ended				3 Months Ended	6 Months Ended	3 Months Ended	6 Months Ended
Debt (Narrative) (Details) (USD $)	Jun. 30, 2011	Dec. 31, 2010	Jun. 30, 2011 Senior Credit Facility [Member]	Dec. 31, 2010 Senior Credit Facility [Member]	Jun. 30, 2011 Senior Credit Facility [Member] Minimum [Member]	Jun. 30, 2011 Senior Credit Facility [Member] Maximum [Member]	Dec. 31, 2010 Term Loan December 31, 2010 [Member]	Jun. 11, 2007 2010 Senior Convertible Notes [Member]	Jun. 11, 2007 2012 Senior Convertible Notes [Member]	Jun. 30, 2011 2012 Senior Convertible Notes [Member]	Dec. 31, 2010 2012 Senior Convertible Notes [Member]	Jun. 30, 2011 2016 Senior Convertible Notes [Member]	Jun. 30, 2011 2016 Senior Convertible Notes [Member]	Jun. 15, 2011 2016 Senior Convertible Notes [Member]	Jun. 30, 2011 Revolving Credit Component [Member]	Dec. 31, 2010 Revolving Credit Component [Member]	Jun. 30, 2011 Non-cash Interest [Member] 2016 Senior Convertible Notes [Member]	Jun. 30, 2011 Non-cash Interest [Member] 2016 Senior Convertible Notes [Member]	Jun. 30, 2011 Cash Interest [Member] 2016 Senior Convertible Notes [Member]	Jun. 30, 2011 Cash Interest [Member] 2016 Senior Convertible Notes [Member]	Jun. 30, 2011 Option i [Member] Senior Credit Facility [Member] Minimum [Member]	Jun. 30, 2011 Option i [Member] Senior Credit Facility [Member] Maximum [Member]	Jun. 30, 2011 Option ii [Member] Option X [Member] Senior Credit Facility [Member]	Jun. 30, 2011 Option ii [Member] Option Y [Member] Senior Credit Facility [Member]	Jun. 30, 2011 Option ii [Member] Option Z [Member] Senior Credit Facility [Member]
Senior credit facility size increased to			$ 600,000,000
Portion of the debt proceeds that was classified as equity at the time of the offering								16,400,000	30,600,000			43,200,000	43,200,000
Effective interest rate implicit in the liability component								6.50%	6.80%				5.60%
Financing fees			1,300,000									6,300,000	6,300,000
Carrying amount of liability	345,687,000	155,154,000								158,500,000	155,200,000	187,200,000	187,200,000
Unamortized discount										6,500,000	9,800,000	42,800,000	42,800,000
Principal amount outstanding								165,000,000	165,000,000	165,000,000	165,000,000	230,000,000	230,000,000	230,000,000
Prior revolving credit component				450,000,000
Reallocated term loan			150,000,000
Prior revolving and senior credit facility's maturity date				August 10, 2015
Available borrowings under senior secured revolving credit facility			455,600,000
Line of Credit Facility, Expiration Date			June 8, 2016
Interest rates available to the Company at it's option																					1.00%	1.75%
Interest rates descriptions																							the weighted average overnight Federal funds rate, as published by the Federal Reserve Bank of New York, plus 0.5%	the prime lending rate of Bank of America, N.A.	the one-month Eurodollar Rate plus 1.0%
Consolidated funded indebtedness			40,000,000
Additional commitments			200,000,000
Line of credit, collateral			substantially all of the assets of the Company's U.S. subsidiaries, excluding intangible assets.
Line of credit, covenant terms			The Senior Credit Facility is subject to various financial and negative covenants
Line of credit, commitment fee percentage					0.15%	0.30%
Interest rate on debt							2.60%	2.75%	2.375%			1.625%	1.625%		1.50%	2.50%
Fair value of outstanding borrowings			131,700,000							166,500,000		231,400,000	231,400,000
Principal amount outstanding							148,100,000								144,400,000	100,000,000
Common stock based on initial conversion rate										15.3935			17.4092
Principal amount to be considered for conversion purpose										1,000			1,000
Initial conversion price										64.96		57.44	57.44
Cost of call transactions									30,400,000					42,900,000
Proceeds from warrant transactions									12,200,000					28,500,000
Strike price of the call transaction										$ 64.96		$ 57.44	$ 57.44
Strike price of the warrant transactions										$ 77.96		$ 70.05	$ 70.05
Maximum selling price of company's common stock										130.00%			150.00%
Principal amount of notes per average trading price										1,000			1,000
Maximum average conversion value of the Notes										97.00%			98.00%
Convertible debt maturity date													December 15, 2016
"Debt instrument, call and warrant transactions descriptions										In connection with the issuance of the 2012 Notes, the Company entered into call transactions and warrant transactions, primarily with affiliates of the initial purchasers of the Notes (the "hedge participants"). The cost of the call transactions to the Company was approximately $30.4 million, representing options to buy 2.5 million shares from the hedge participants at an initial strike price of approximately $64.96 per share, subject to customary anti-dilution adjustments. These transactions are expected to reduce the potential dilution upon conversion of the notes. The Company received approximately $12.2 million of proceeds from the warrant transactions, representing an obligation to potentially deliver 2.5 million shares to the hedge participants at an initial strike price of approximately $77.96 per share, subject to customary anti-dilution adjustments. These warrant transactions expire on various dates between August 30, 2012 and January 23, 2013 and could separately have a dilutive effect on the Company's earnings per share if the market price of its common stock exceeds the strike price of the warrants.			In connection with the issuance of the 2016 Notes, the Company entered into call transactions and warrant transactions, primarily with affiliates of the initial purchasers of the Notes (the "hedge participants"). The cost of the call transactions to the Company was approximately $42.9 million, representing options to buy 4.0 million shares from the hedge participants at an initial strike price of $57.44 per share, subject to customary anti-dilution adjustments. These transactions are expected to reduce the potential dilution upon conversion of the notes. The Company received approximately $28.5 million of proceeds from the warrant transactions, representing an obligation to potentially deliver 4.0 million shares to the hedge participants at an initial strike price of $70.05 per share, subject to customary anti-dilution adjustments. The earliest expiration of these warrant transactions is March 15, 2017 and they continue to expire through the 100th scheduled trading day thereafter, as defined in the indenture. The warrants could separately have a dilutive effect on the Company's earnings per share if the market price of its common stock exceeds the strike price of the warrants.
Interest recognized												500,000	500,000				300,000	300,000	200,000	200,000
Expensed incremental financing costs			400,000
Expensed previously capitalized financing costs			$ 400,000
Warrant and call transactions										2,500,000		4,000,000	4,000,000

Debt (Components Of Interest Expense) (USD $) In Thousands, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2011	Jun. 30, 2010	Jun. 30, 2011	Jun. 30, 2010
2010 Senior Convertible Notes [Member]
Interest expense		$ 837		$ 2,020
2012 Senior Convertible Notes [Member]
Interest expense	2,678	2,566	5,326	5,105
Non-cash Interest [Member] \| 2010 Senior Convertible Notes [Member]
Interest expense		480		1,190
Non-cash Interest [Member] \| 2012 Senior Convertible Notes [Member]
Interest expense	1,698	1,586	3,367	3,146
Cash Interest [Member] \| 2010 Senior Convertible Notes [Member]
Interest expense		357		830
Cash Interest [Member] \| 2012 Senior Convertible Notes [Member]
Interest expense	$ 980	$ 980	$ 1,959	$ 1,959

Derivative Instruments (Narrative) (USD $)	6 Months Ended	12 Months Ended
Derivative Instruments (Narrative) (USD $)	Jun. 30, 2011	Dec. 31, 2010
Interest rate swap expiration date	August 10, 2015
Period for interest rate hedge to be reclassified to earnings	twelve
Interest Rate Swap [Member]
Net pre-tax losses recorded in OCI	$ 2,100,000
Forward Contracts [Member]
Foreign currency hedge contracts	$ 0	$ 0

Derivative Instruments (Summary Of Fair Value In Balance Sheet For Derivatives Designated As Hedging Instruments) (Details) (Interest Rate Swap [Member], USD $)

6 Months Ended

12 Months Ended

Jun. 30, 2011

Dec. 31, 2010

Notional amount of interest rate derivatives

$ 144,400,000

$ 148,100,000

Reduction in notional amount of interest rate derivatives in next twelve months

10,300,000

8,400,000

Accrued Expenses and Other Current Liabilities [Member]

Derivative Fair Value Of Derivative Liability

2,103,000

^[1],[2]

2,095,000

^[1],[2]

Other Assets [Member]

Derivative Fair Value Of Derivative Asset

$ 196,000

^[1],[2]

$ 1,825,000

^[1],[2]

[1]	The Company classifies derivative assets and liabilities as current based on the cash flows expected to be incurred within the following 12 months.
[2]	At June 30, 2011 and December 31, 2010, the notional amount related to the Company's sole interest rate swap was $144.4 million and $148.1 million, respectively. In the subsequent twelve months, the Company expects to reduce these amounts by $10.3 million and $8.4 million, respectively.

Derivative Instruments (Effect Of Derivative Instruments Designated As Cash Flow Hedges On Statements Of Operations) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended	6 Months Ended	3 Months Ended	6 Months Ended
	Jun. 30, 2010 Other Income (Expense) [Member] Currency Hedge Contracts [Member]	Jun. 30, 2010 Other Income (Expense) [Member] Currency Hedge Contracts [Member]	Jun. 30, 2011 Interest (Expense) [Member] Interest Rate Swap [Member]	Jun. 30, 2011 Interest (Expense) [Member] Interest Rate Swap [Member]
Amount of Gain (Loss) Recognized in AOCI Effective Portion	$ (1,018)	$ (1,734)	$ (2,958)	$ (2,781)
Amount of Gain (Loss) Reclassified from AOCI Into Earnings-Effective Portion	$ (1,009)	$ (1,718)	$ (570)	$ (1,143)

Stock-Based Compensation (Details) (USD $)	6 Months Ended
Stock-Based Compensation (Details) (USD $)	Jun. 30, 2011	Jun. 30, 2010
Proceeds from stock options exercises	$ 3,297,000	$ 4,633,000
Requisite service periods of Performance stock, restricted stock and contract stock awards	4 years
Employee Stock Option [Member]
Total unrecognized compensation costs	1,300,000
Weighted-average period for cost recognition, years	2
Stock options granted	34,000	59,000
Proceeds from stock options exercises	3,300,000	4,600,000
Restricted Stock [Member]
Total unrecognized compensation costs	13,100,000
Weighted-average period for cost recognition, years	2.0
Contract Stock / Stock units granted to CEO	165,000
Expense of Contract Stock / Stock units granted to CEO	$ 8,400,000

Treasury Stock (Treasury Stock Activity) (Details) (USD $) Share data in Thousands, unless otherwise specified	1 Months Ended	6 Months Ended
	Oct. 29, 2010	Jun. 30, 2011
Shares repurchased		$ 57,009,000
Shares repurchased		1,213
Stock repurchase program, authorized amount	75,000,000
Amount available for share repurchase under this latest authorization		55,500,000
Board Approved Buyback Program [Member]
Shares repurchased		19,439,000
Shares repurchased		408
2016 Senior Convertible Notes [Member]
Shares repurchased		$ 37,570,000
Shares repurchased		805

Retirement Benefit Plans (Defined Benefit Pension Plans) (Details) (USD $)	3 Months Ended			6 Months Ended
	Jun. 30, 2011	Mar. 31, 2011	Jun. 30, 2010	Jun. 30, 2011	Jun. 30, 2010
Retirement Benefit Plans
Service cost	$ 26,000		$ 26,000	$ 53,000	$ 53,000
Interest cost	169,000		155,000	334,000	313,000
Expected return on plan assets	(149,000)		(119,000)	(295,000)	(244,000)
Recognized net actuarial loss			36,000		74,000
Net period benefit cost	46,000		98,000	92,000	196,000
Contribution to defined benefit pension plans				400,000	500,000
Reduction in projected benefit obligation		$ 300,000

Income Taxes (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2011	Jun. 30, 2010	Jun. 30, 2011	Jun. 30, 2010
Reported tax rate	65.00%	28.10%	27.60%	24.80%
Uncertain Taxes			$ 2.3
Correction to a deferred tax asset	1.7		1.7
New Jersey [Member]
Deferred tax assets	$ 0.7

Net Income Per Share (Details) (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2011	Jun. 30, 2010	Jun. 30, 2011	Jun. 30, 2010
Net Income Per Share
Net Income	$ 699	$ 15,157	$ 12,186	$ 30,379
Weighted average common shares outstanding - Basic	29,556,000	29,855,000	29,559,000	29,672,000
Basic net income per common share	$ 0.02	$ 0.51	$ 0.41	$ 1.02
Net income	$ 699	$ 15,157	$ 12,186	$ 30,379
Weighted average common shares outstanding - Basic	29,556,000	29,855,000	29,559,000	29,672,000
Stock options and restricted stock	622,000	544,000	595,000	610,000
Weighted average common shares for diluted earnings per share	30,178,000	30,399,000	30,154,000	30,282,000
Diluted net income per share	$ 0.02	$ 0.50	$ 0.40	$ 1.00
Impact of participating securities on rounding of earning or loss per share			$ 0.01
Outstanding stock options	1,500,000	1,900,000	1,500,000	1,900,000
Anti-dilutive stock options	100,000	700,000	200,000	700,000

Comprehensive (Loss) Income (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2011	Jun. 30, 2010	Jun. 30, 2011	Jun. 30, 2010
Comprehensive (Loss) Income
Net Income	$ 699	$ 15,157	$ 12,186	$ 30,379
Foreign currency translation adjustment	4,934	(16,704)	18,400	(27,933)
Change in unrealized gain on derivatives, net of tax	(1,361)	(5)	(933)	(11)
Pension liability adjustment, net of tax	(77)		185
Comprehensive income (loss)	$ 4,195	$ (1,552)	$ 29,838	$ 2,435

- Definition

The portion of consolidated profit or loss for the period, net of income taxes, which is attributable to the parent. If the entity does not present consolidated financial statements, the amount of profit or loss for the period, net of income taxes.

+ References+ Details

- Definition

The after-tax amount of the change in the additional pension liability not yet recognized pursuant to FAS 87 par 37 and 38 as a net periodic pension cost. If the additional pension liability required to be recognized exceeds the unrecognized prior service costs, then the excess (which is the net loss not yet recognized as net periodic pension cost) is to be recorded as a reduction of other comprehensive income, before adjusting for tax effects. If in a subsequent measurement, the amount of minimum liability is eliminated or adjusted, this adjustment is offset against other comprehensive income in Accumulated Comprehensive Income. This line also includes changes in an entity's share of an equity investee's increase (decrease) in additional pension liability not yet recognized as a net periodic pension cost. Eliminated upon adoption of FAS 158.

+ References+ Details

Segment And Geographic Information (Revenues By Major Geographic Area) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2011	Jun. 30, 2010	Jun. 30, 2011	Jun. 30, 2010
Total revenues	$ 193,329	$ 178,595	$ 374,370	$ 351,293
United States [Member]
Total revenues	144,872	138,760	278,172	268,123
Europe [Member]
Revenue from foreign countries	25,209	20,076	50,296	44,228
Asia Pacific [Member]
Revenue from foreign countries	11,625	9,174	22,372	18,411
Other Foreign [Member]
Revenue from foreign countries	$ 11,623	$ 10,585	$ 23,530	$ 20,531

Commitments And Contingencies (Details) (USD $) In Millions, unless otherwise specified	1 Months Ended	6 Months Ended	9 Months Ended
	Jan. 31, 2011	Jun. 30, 2011	Sep. 30, 2009
Commitments And Contingencies
The Company allegedly owes an additional payment related to revenue performance of trade sales			$ 6.7
Original accrual amount for settlement			3.4
Expense accrued by company in the estimate of settlement		4.6
Additional amount due under the asset purchase agreement		1.2
Alleged amount owed reduced	5.7
Product liability accrual		$ 4.8